Clinical and Molecular Hepatology (대한간학회지)

The Korean Association for the Study of the Liver (대한간학회)
권호 표지

Differential Diagnosis of Diabetes Mellitus caused by Liver Cirrhosis and Other Type 2 Diabetes Mellitus

간경변증 환자에서 유발된 당뇨병과 다른 제2형 당뇨병 환자의 감별진단

Kim, Min-Geun;Choi, Won-Choong
김민근;최원충

  • Published : 20060000
⟨ Previous Next ⟩

Abstract

The liver plays important roles in the homeostasis of glucose metabolism since it acts as a major target organ for insulin and a site for gluconeogenesis and glycogen storage. Diabetes mellitus (DM) commonly develops in patients with liver cirrhosis as the result of hepatocyte dysfunction and/or inadequate mass. To assess differences between DM due to liver cirrhosis (hepatogenous DM) and the other type 2 DM, we compared the patterns of hyperglycemia and hyperinsulinemia in hepatogenous DM with those observed in type 2 DM. Methods: 18 diabetic patients with liver cirrhosis (caused by alcohol, n=8; HBV, n=5; HCV, n=2; others, n=3) were matched with 18 type 2 diabetic patients without liver cirrhosis for age and gender. None of the patients or controls had been treated with insulin or $\beta$-blockers. The level of glycosylated hemoglobin ($HbA_{1c}$), fasting plasma glucose (FPG), postprandial plasma glucose (PP2h), fasting plasma C-peptide and insulin were measured. Results: The ratio of PP2h/FPG (2.27 vs. 1.69), fasting insulin (23.2: 11.6 ${\mu}IU$/mL) and HOMA-IR index (8.38 vs. 3.52) were significantly higher in hepatogenous DM than the other type 2 DM (P<0.05). PP2h, fasting C-peptide and ratio of fasting insulin/C-peptide tend to be higher in hepatogenous DM than those of controls, but which were not statistically significant. Conclusions: The ratio of PP2h/FPG and fasting plasma insulin differentiated hepatogenous DM from the other type 2 DM. Insulin resistance in liver cirrhosis was higher than the other type 2 DM, and impaired hepatic insulin degradation might be an important mechanism of hyperinsulinemia in liver cirrhosis.

목적: 간은 혈당조절호르몬인 인슐린의 대사에 중요한 장기이며, 자체의 포도당 합성 및 글리코겐의 저장 또는 분해기능으로 체내 포도당 농도를 일정하게 유지하는 당 대사에 중요한 장기이다. 간경변증 환자에서 당뇨병은 흔히 발생되지만, 임상 형태 및 예후는 다른 제2형 당뇨병과 차이가 있는 것으로 알려져 있다. 간경변성 당뇨병과 다른 제2형 당뇨병의 감별을 위하여 임상에서 쉽게 시행할 수 있는 혈액검사로 알아보기 위해 연구를 시행하였다. 대상과 방법: 당뇨병이 동반된 간경변증 환자 18명과 간경변증이 없는 유사 연령, 성별의 제2형 당뇨병 환자 18명의 FPG, PP2h, $HbA_{1c}$, 공복혈장인슐린, 공복혈장C-펩타이드를 측정하였고, PP2h/ FPG의 비, 공복혈장인슐린/C-펩타이드 비, 인슐린저항성의 지표로서 HOMA IR index[fasting insulin (mIU/L)$\time$fasting glucose (mmol/L)/22.5]를 계산하여 비교하였다. 결과: PP2h/FPG의 비(2.27 vs. 1.69), 공복혈장인슐린(23.2 : 11.6 ${\mu}IU$/ mL), HOMA IR index는(8.38 vs. 3.52) 간경변성 당뇨병 환자군이 다른 제2형 당뇨병 환자군보다 의미 있게 높았다(P<0.05). PP2h, 공복혈장C-펩타이드, 공복혈장인슐린/C-펩타이드 비는 간경변성 당뇨병 환자군에서 높은 경향은 있었으나 통계에서 유의하지는 않았다. FPG, $HbA_{1c}$는 양군 간의 차이가 없었다. 결론: 간경변성 당뇨병 환자군과 다른 제2형 당뇨병 환자와의 감별에 PP2h/FPG의 비, 공복혈장인슐린 및 인슐린저항성(HOMA-IR)검사가 도움이 될 것으로 생각한다.

Keywords

References

  1. Harrison SA. Liver disease in patient with diabetes mellitus. J Clin Gastroenterol 2006;40:68-76 https://doi.org/10.1097/01.mcg.0000190774.91875.d2
  2. Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994;19:616-627 https://doi.org/10.1002/hep.1840190312
  3. Cavallo-Perin P, Cassader M, Bozzo C, Bruno A, Nuccio P, Dall'Omo AM, et al. Mechanism of insulin resistance in human liver cirrhosis: Evidence of a combined receptor and postreceptor defect. J Clin Invest 1985;75:1659-1665 https://doi.org/10.1172/JCI111873
  4. Holder A Der Diabetes Mellitus. In: Naunyn B, ed. Nothnagels Hanclbuch. Wien: A Holder, 1906
  5. Bianchi G, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994:20:119-125
  6. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver disease. J Gastrcenterol Hepatol 2002;17:677-681 https://doi.org/10.1046/j.1440-1746.2002.02755.x
  7. World Health Organization: Definition, Diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. Geneva, World Health Organization, 1999
  8. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA Modeling. Diabetes Care 2004;27:1487-1495 https://doi.org/10.2337/diacare.27.6.1487
  9. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hill JM, Fung C, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-379 https://doi.org/10.1053/jhep.2002.30692
  10. Merli M, Leonetti F, Riggio O, Valeriano V, Ribaudo MC, Strati F, et al. Glucose intolerance and insulin resistance in cirrhosis are normalized after liver transplantation. Hepatology 1999:30:649-654 https://doi.org/10.1002/hep.510300306
  11. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985:313:1256-1262 https://doi.org/10.1056/NEJM198511143132004
  12. Selberg O, Burchert W, vd Hoff J, Meyer GJ, Hundeshagen H, Radoch E, et al. Insulin resistance in liver cirrhosis. Positron-emission tomography scan analysis of skeletal muscle glucose metabolism. J Clin Invest 1993;91: 1897-1902 https://doi.org/10.1172/JCI116407
  13. Nolte W, Hartmann H, Ramadori G. Glucose metabolism and liver cirrhosis. Exp Clin Endocrinol Diabetes 1995;103:63-74 https://doi.org/10.1055/s-0029-1211331
  14. Imano E, Kanda T, Nakatani Y, Motomura M, Arai K, Matsuhisa M, et al. Impaired splanchnic and peripheral glucose uptake in liver cirrhosis. J Hepatol 1999;31:469-473 https://doi.org/10.1016/S0168-8278(99)80039-7
  15. Bosch J, Gomis R, Kravetz D, Casamitjana R, Teres J, Rivera F, Rodes J. Role of spontaneous portal-systemic shunting in hyperinsulinism of cirrhosis. Am J Physiol 1984;247:G206-G212
  16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419 https://doi.org/10.1007/BF00280883
  17. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63 https://doi.org/10.2337/diacare.23.1.57
  18. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Furuta M, Araki-Sasaki R, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 2001;24: 362-365 https://doi.org/10.2337/diacare.24.2.362
  19. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-848 https://doi.org/10.1053/j.gastro.2003.11.056
  20. Kwon SY, Kim SS, Kwon OS, Kwon KA, Chung MG, Park DK, et al, Prognostic significance of glycaemic control in patients with HEV and HCV-related cirrhosis and diabetes mellitus. Diabet Med 2005;22:1530-1535 https://doi.org/10.1111/j.1464-5491.2005.01687.x